scPharmaceuticals Inc. Announces Nasdaq Delisting and SEC Deregistration Following Merger Completion
scPharmaceuticals Inc. has announced its delisting from the Nasdaq Global Select Market following the completion of a merger. Trading of its shares was halted on October 7, 2025, and Nasdaq will file Form 25 with the SEC to remove the shares from listing. The company will also file Form 15 to terminate its registration and suspend reporting obligations under the Securities Exchange Act as part of its transition post-merger.
scPharmaceuticals Inc. Announces Nasdaq Delisting Following Merger scPharmaceuticals Inc. has announced that, following the completion of a merger, it will delist its shares from the Nasdaq Global Select Market. Trading of the company’s shares was halted prior to the market opening on October 7, 2025. Nasdaq is expected to file Form 25 with the SEC on the same date to remove scPharmaceuticals’ shares from listing and registration. The company also plans to file Form 15 with the SEC to terminate its registration and suspend its reporting obligations under the Securities Exchange Act. These moves are part of the company’s transition following the closing of the merger. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. scPharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-232754), on October 07, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
